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grams on a well-characterized population of probands meeting
ARVD task force criteria and their family members. It is our hope
that with these data, the diagnostic utility of these abnormal
echocardiographic parameters found in the probands can be tested
in family members at risk for ARVD who are asymptomatic and
do not yet meet full task force diagnostic criteria.
Currently, there remains no single defined “gold standard” test for
ARVD whether symptomatic or asymptomatic, but given its nonin-
vasive nature and ease of repeated performance, even in the presence
of implantable cardiovascular-defibrillators, transthoracic echocardi-
ography is a reasonable tool to study progression of this disease.
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Safety of Dobutamine
Contrast Stress Echocardiography
We agree with Tsutsui et al. (1) that dobutamine real-time
contrast echocardiography is both a safe and feasible technique.
Sonovue (Bracco Imaging, Milan, Italy) is commonly used in
Europe for left ventricular opacification, although it is not ap-
proved by the U.S. Food and Drug Administration (2). In Europe,
the summary of product characteristics of Sonovue was changed
following safety concerns in patients with significant coronary
artery disease (CAD). We have previously published similar
findings to those of Tsutsui et al. (3) from our experience using
both Sonovue and Optison during dobutamine stress echocardi-
ography in over 400 patients and low mechanical index real-time
imaging. Specifically, we found no increased incidence of arrhyth-
mia, ectopy, hypotension, or other side effects, and once again no
mortality or myocardial infarctions.
The data from Tsutsui et al. (1) and also our center should reassure
echocardiographers of the safety of contrast agents during dobutamine
stress. It is also important to remember that up to 30% of echocar-
diograms may be nondiagnostic owing to poor image quality, and
there are implications for both false positive and false negative results.
A false negative result may lead to false reassurance to a patient with
significant CAD, whereas a false positive test or nondiagnostic test
may lead to further noninvasive or invasive imaging. Other noninva-
sive tests are not without small but definite risks. The mortality from
single-photon emission computed tomography is reported at 0.05%
(4), and the mortality from coronary angiography is 0.03% to 0.26%
(5) as well as other peripheral vascular and cerebrovascular morbidi-
ties. It is therefore important that image quality during dobutamine
stress echocardiography is not sacrificed and the use of contrast
appears safe, feasible, and effective.
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REPLY
We thank Mr. Timperley and Dr. Becher for their comments
regarding the safety of contrast echocardiography (1). Their findings
reinforce our results demonstrating no increase in the incidence of
adverse effects when using intravenous (IV) second-generation con-
trast agents and low mechanical index real-time imaging during
dobutamine stress echocardiography. Nevertheless, we would like to
emphasize that in our study (1), IV contrast agents were also used for
the assessment of myocardial perfusion.We tested two contrast agents
already approved by the Food and Drug Administration using the
same doses as recommended for the enhancement of left ventricular
opacification during stress testing (2). The high sensitivity of the low
mechanical index pulse scheme techniques for detecting small
amounts of microbubbles in the myocardium allowed for simulta-
neous evaluation of both contrast-enhanced wall motion and myo-
cardial perfusion with high feasibility and good safety profile. Con-
sistent with previous studies (3,4), we demonstrated that the analysis
of myocardial perfusion increased the sensitivity and diagnostic
accuracy of dobutamine stress echocardiography for detecting angio-
graphically significant coronary artery disease. Thus, our findings
demonstrate the potential use of real-time myocardial contrast echo-
cardiography as an alternative and safe method of perfusion imaging
during stress testing.
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CORRECTION
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The volume cutpoints in the first row and the last two rows of Table 1 were printed incorrectly. The full correct table is printed below.
The authors apologize for this error.
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Table 1. Baseline Characteristics of Patients According to Physician-Volume Quartile
ICD Annualized Volume
1–10 11–18 19–28 29
p Value(n  2,487) (n  2,559) (n  2,336) (n  2,472)
Age (yrs)
65–69 562 (22.6%) 593 (23.2%) 507 (21.7%) 564 (22.8%) 0.38
70–74 712 (28.6%) 748 (29.2%) 690 (29.5%) 727 (29.4%)
75–79 734 (29.5%) 729 (28.5%) 707 (30.3%) 676 (27.4%)
80–84 373 (15.0%) 384 (15.0%) 320 (13.7%) 403 (16.3%)
85 106 (4.3%) 105 (4.1%) 112 (4.8%) 102 (4.1%)
Female 536 (21.6%) 569 (22.2%) 489 (20.9%) 536 (21.7%) 0.74
Race
White 2,251 (90.5%) 2,386 (93.2%) 2,155 (92.3%) 2,313 (93.6%) 0.01
Black 163 (6.6%) 117 (4.6%) 137 (5.9%) 121 (4.9%)
Other 73 (2.9%) 56 (2.2%) 44 (1.9%) 38 (1.5%)
Charlson comorbidity score
0 1,197 (48.1%) 1,144 (44.7%) 1,104 (47.3%) 1,095 (44.3%) 0.18
1 800 (32.2%) 892 (34.9%) 785 (33.6%) 858 (34.7%)
2 350 (14.1%) 388 (15.2%) 322 (13.8%) 376 (15.2%)
3 or more 140 (5.6%) 135 (5.3%) 125 (5.4%) 143 (5.8%)
Urgency of admission
Outpatient 244 (9.8%) 233 (9.1%) 255 (10.9%) 196 (7.9%) 0.01
Elective 726 (29.2%) 711 (27.8%) 708 (30.3%) 775 (31.4%)
Urgent 710 (28.6%) 707 (27.6%) 710 (30.4%) 829 (33.5%)
Emergency 807 (32.5%) 908 (35.5%) 663 (28.4%) 672 (27.2%)
Pacemaker annualized volume 0.01
1–20 1,309 (52.6%) 586 (22.9%) 349 (14.9%) 182 (7.4%)
64 145 (5.8%) 380 (14.9%) 754 (32.3%) 1,184 (47.9%)
ICD  implantable cardioverter-defibrillator.
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